Research & Development
FDA grants Breakthrough Therapy designation to Clarity Pharmaceuticals' prostate cancer imaging agent
12 November 2026 - Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals Ltd (ASX: CU6) said on Thursday the US Food and Drug Administration (FDA) has granted Breakthrough Ther...
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
12 November 2026 - Clinical-stage biopharmaceutical company Traws Pharma, Inc. (NASDAQ: TRAW) on Thursday reported final results from a 92-patient Phase 2a study of ratutrelvir, its investigational on...
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
12 November 2026 - Shanton Pharma, a China-based, clinical-stage biotech developing a novel treatment for hyperuricaemia and gout in adults, announced on Wednesday that it has reached an agreement wit...
MellingMedical partners with CellTivity Scientific to enhance diagnostic cancer sampling for federal healthcare providers
12 November 2026 - MellingMedical, a US-based company that provides veterans with access to healthcare, announced on Wednesday a new strategic relationship with CellTivity Scientific, a US-based compa...
Ascletis announces submission of US IND application for oral obesity combination therapy
11 November 2026 - Biotechnology company Ascletis Pharma Inc (HKEX: 1672) reported on Wednesday that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administrati...
Abbisko Therapeutics' PIMJETMI receives US FDA approval to treat tenosynovial giant cell tumour (TGCT)
11 November 2026 - Abbisko Therapeutics Co Ltd (HKEX code: 02256.HK), a China-based biopharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has approved PIMJETMI...